Logo CICANCER

KRAS driven lung adenocarcinoma depends on ERBB signaling

KRAS driven lung adenocarcinoma depends on ERBB signaling

Emilio Casanova-Hevia

Ludwig Boltzmann Institute Cancer Research [Vienna, Austria]

Date: 30/05/2019
Time: 12:30:00
Salón de actos del Centro de Investigación del Cáncer
Carmen Guerrero

Several clinical trials using first generation EGFR Tyrosine Kinase Inhibitors (TKIs, erlotinib and gefitinib) in patients suffering of lung adenocarcinoma (AC) harboring activating mutations in the KRAS gene have shown disappointing results. Therefore, it has become a dogma that KRAS driven lung AC do not respond to TKIs and targeting EGFR is not considered a therapeutic option to treat patients suffering of KRAS mutated lung AC. In agreement we that, we have sho